Morning akinesia and nocturnal immobility in Parkinson´s disease
CP-012

Contera Pharma is developing CP-012 as a novel, delayed, dual-pulse formulation of levodopa and carbidopa to be taken at bedtime in addition to normal medication and prevent the onset of nocturnal symptoms and early morning akinesia. Contera Pharma has full ownership and holds global rights to the program.